Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors.

[1]  P. Nordlund,et al.  Fragment-based ligand design of novel potent inhibitors of tankyrases. , 2013, Journal of medicinal chemistry.

[2]  I. Collins,et al.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies , 2013, Expert opinion on drug discovery.

[3]  M. Walton,et al.  Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors , 2012, Journal of medicinal chemistry.

[4]  S. Robinson,et al.  CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs , 2012, Clinical Cancer Research.

[5]  J. Breed,et al.  Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. , 2012, Journal of medicinal chemistry.

[6]  Takashi Asai,et al.  The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells , 2012, Molecular Cancer Therapeutics.

[7]  Gary Box,et al.  The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 , 2010, Molecular Cancer Therapeutics.

[8]  Johanna M Jansen,et al.  Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. , 2009, Journal of medicinal chemistry.

[9]  Chang Park,et al.  Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. , 2007, Journal of medicinal chemistry.

[10]  G. Schwartz,et al.  Targeting Checkpoint Kinase 1 in Cancer Therapeutics , 2007, Clinical Cancer Research.

[11]  E. Moler,et al.  CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo , 2007, Clinical Cancer Research.

[12]  Z. Tao,et al.  Chk1 inhibitors for novel cancer treatment. , 2006, Anti-cancer agents in medicinal chemistry.

[13]  Z. Ni,et al.  4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[14]  M. Wiesmann,et al.  Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Gaoquan Li,et al.  1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. , 2005, Journal of medicinal chemistry.

[16]  D. Parry,et al.  Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint , 2005, Cell cycle.

[17]  K. Anderson,et al.  CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. , 2000, Blood.

[18]  S. Rault,et al.  Thiaisatoic anhydrides: Efficient synthesis under microwave heating conditions and study of their reactivity , 1998 .

[19]  T. Fischmann,et al.  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2. , 2011, Bioorganic & medicinal chemistry letters.